The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
Journal Title: Journal of Surgery : Concepts & Practice - Year 2024, Vol 29, Issue 5
Abstract
Bone-modifying agents (BMAs), including bisphosphonate (BP) and denosumab, can reduce bone-related events caused by breast cancer bone metastasis. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update” was published in Journal of Clinical Oncology in January 2022. The new “2022 version Guideline” suggested that the use of BP should be discussed for all postmenopausal patients with early breast cancer who are indicated for adjuvant therapy. Recommended drugs included zoledronate, clodronate, and ibandronate, and the recommended duration of BP was 2-3 years. Owing to the inconsistent results of the ABCSG-18 and D-CARE trials and the lack of data directly comparing denosumab with BP in early breast cancer, the use of denosumab in adjuvant therapy was not recommended. In conclusion, the role of BP in the adjuvant treatment of early breast cancer has been further affirmed, while the value of denosumab remains unclear.
Authors and Affiliations
Yujie LU, Siji ZHU
Keywords
Related Articles
- EP ID EP761794
- DOI 10.16139/j.1007-9610.2024.05.07
- Views 6
- Downloads 0
Innovation in the era of big data: advancing abdominal wall mechanics research through machine learning and artificial intelligence
Research in abdominal wall mechanics is progressively overcoming the limitations of traditional assessment methods with the application of machine learning and artificial intelligence technologies. By leveraging deep lea...
Clinical application of preoperative MRI examination in breast-conserving surgery for ductal carcinoma in situ
[Objective:] To evaluate the relationship between preoperative magnetic resonance imaging (MRI) examination and the success rate and prognosis of breast-conserving surgery in ductal carcinoma in situ (DCIS) patients. [Me...
Emerging developments in immune checkpoint inhibitor therapy for gastroenteropancreatic neuroendocrine neoplasm
Immunotherapies targeting immune checkpoints have undergone rapid evolution, and have been preliminary explored in treatment of gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) in recent years. However, their pot...
Summary and prospect of perioperative comprehensive treatment for gastric cancer in China
Most of the patients with gastric cancer in China have been at the middle and advanced stages during diagnostic and treatment with poor prognosis overall. Perioperative radiotherapy, chemotherapy, immune therapy and othe...
Interpretation of the 2022 edition of “guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis in China”
“Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis in China” (2022) (referred to as the “guidelines”) was officially published in August 2022 in the Chinese Journal of Endocrin...